Pharma - Animal Stocks in India

4-Factor Sector Score

An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is guarded: positive earnings, positive 5–60% three-year EPS growth, and a positive P/E are required.

Revenue Scale & Growth Durability

Viyash Scientific Ltd has the highest Revenue among the 3 Pharma - Animal companies compared here, at ₹3,069 crore. NGL Fine Chem Ltd is next at ₹501 crore. The same company also holds the highest Revenue growth, at 58.6%. 3 of 3 companies report a comparable reading, the latest through Mar 2026.

What the numbers say: Viyash Scientific Ltd is the scale leader at ₹3,069 crore, 512.6% ahead of NGL Fine Chem Ltd. Viyash Scientific Ltd's growth is 58.6% from a ₹3,069 crore base, with 20 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.

Investor read: Viyash Scientific Ltd is the scale benchmark; Viyash Scientific Ltd is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.

This conclusion weakens if: Viyash Scientific Ltd's growth falls below Viyash Scientific Ltd's for two consecutive comparable reports while operating margin also compresses.

Operating Economics & Margin Trend

Hester Biosciences Ltd has the highest OPM among the 3 Pharma - Animal companies compared here, at 34%. Viyash Scientific Ltd is next at 20%. The same company also holds the highest Margin change, at +11 percentage points. 3 of 3 companies report a comparable reading, the latest through Mar 2026.

What the numbers say: Hester Biosciences Ltd leads both opm at 34% and margin change at +11 percentage points.

Investor read: Hester Biosciences Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current margin change signal.

Profit Scale & Acceleration

Viyash Scientific Ltd has the highest Net profit among the 3 Pharma - Animal companies compared here, at ₹206 crore. Hester Biosciences Ltd is next at ₹57 crore. Hester Biosciences Ltd has the highest Profit growth at the 100% top of the scoring scale, so level and change sit with different companies.

What the numbers say: Viyash Scientific Ltd leads with ₹206 crore of TTM profit, 261.4% above Hester Biosciences Ltd. Hester Biosciences Ltd shows ≥100% on the scoring scale (103.6% uncapped) growth from a ₹57 crore profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.

Investor read: Viyash Scientific Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.

Capacity Spending & Returns On It

No company in this Pharma - Animal comparison reports capital expenditure on a comparable basis, so there is nothing to rank here — 0 of 3 companies have a usable current reading. The section is shown rather than removed so an unavailable metric is not mistaken for one that was quietly left out. Filings were read through Mar 2026.

Debt Load & Balance-Sheet Headroom

NGL Fine Chem Ltd has the lowest Gross debt among the 3 Pharma - Animal companies compared here, at ₹108 crore. Hester Biosciences Ltd is next at ₹195 crore. The same company also holds the lowest Net debt, at ₹65 crore. 3 of 3 companies report a comparable reading, the latest through Mar 2026.

What the numbers say: NGL Fine Chem Ltd has the clearest covered balance-sheet capacity with ₹65 crore and gross debt of ₹108 crore. Absolute debt alone does not identify the strongest balance sheet because company scale differs; net debt and debt-to-equity carry more information.

Investor read: Prioritize net-cash capacity and leverage relative to operating scale, not the smallest absolute rupee debt.

This conclusion weakens if: Net debt rises faster than revenue and profit for two consecutive reported periods.

Return On Capital Employed

NGL Fine Chem Ltd has the highest ROCE among the 3 Pharma - Animal companies compared here, at 17%. Hester Biosciences Ltd is next at 15.2%. The same company also holds the highest ROCE change, at +6.5 percentage points. 3 of 3 companies report a comparable reading, the latest through Mar 2026.

What the numbers say: NGL Fine Chem Ltd leads ROCE at 17%, 1.8 percentage points above Hester Biosciences Ltd. NGL Fine Chem Ltd has the strongest latest improvement at +6.5 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.

Investor read: NGL Fine Chem Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current roce change signal.

Valuation Against Growth & Quality

Viyash Scientific Ltd has the lowest Guarded PEG among the 3 Pharma - Animal companies compared here, at 3.8×. Hester Biosciences Ltd has the lowest P/E at 37.6×, so level and change sit with different companies. 1 of 3 companies report a comparable reading, the latest through Mar 2026.

What the numbers say: Viyash Scientific Ltd has the lowest comparable Guarded PEG at 3.8×. Only 1 of 3 companies pass the guard, so no broad “cheapest stock” conclusion is defensible unless the current multiple, own-history position and growth durability agree.

Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.

This conclusion weakens if: The next two comparable reports reverse the current p/e signal.

Enterprise Value & Book Value

Hester Biosciences Ltd has the lowest EV/EBITDA among the 3 Pharma - Animal companies compared here, at 15.9×. Viyash Scientific Ltd is next at 18.2×. Viyash Scientific Ltd has the lowest P/BV at 3.77×, so level and change sit with different companies. 3 of 3 companies report a comparable reading, the latest through Mar 2026.

What the numbers say: Hester Biosciences Ltd leads ev/ebitda at 15.9×; Viyash Scientific Ltd leads p/bv at 3.77×.

Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.

This conclusion weakens if: The next two comparable reports reverse the current p/bv signal.

Market action

NGL Fine Chem Ltd has the strongest one-year price move in Pharma - Animal at +128%. It also leads on Mansfield relative strength against NIFTY at +60.2%. 3 of 3 covered companies are above zero on that measure. Every line covers 313 weekly closes through 2026-07-17.

What can make this comparison misleading?

This Pharma - Animal comparison names 6 specific ways its own evidence can mislead, all listed below. All 3 companies here report on comparable dates, so no rank carries a stale marker. 2 draw at least one figure from a second feed with too little overlap to cross-check. A high growth rate can still be a low-base artefact.

Which companies are included?

All 3 companies in the canonical Pharma - Animal membership are listed below, largest market value first — nothing is silently dropped, even where a company reports too little to rank. The charts above default to a selective view; this register is the complete set, with each company's own latest reporting date beside it.

AHEAD means the company is beating the index by 5% or more over three months. LAGGING, FUNDAMENTALS UP means it is 20% or more behind over a year while its trailing twelve-month earnings grew 20% or more. Both rules are fixed and applied the same way in every sector.

How was this comparison built?

This comparison is built from the reported filings of 3 Pharma - Animal companies, normalized to a common ₹ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Mar 2026 and market data through 2026-07-24. A second data feed fills gaps only after identity and scale reconciliation, and missing observations are never interpolated.

A second feed is read only after its reported income is matched against the primary source on at least three overlapping periods. Where the two agree the figures fill silently. Where there is too little shared history to compare, the figures are still drawn — they are the only evidence there is — and marked ⚠ unverified everywhere they appear. Where the two are known to disagree, nothing from the second feed is drawn and the affected company is named under the chart it is missing from. Every company's standing is listed in the register above.

Pharma - Animal company comparison FAQs

These 17 answers restate the Pharma - Animal comparison above in question form. Every one is computed from the same 3 companies and the same reported filings as the rankings and charts, current through Mar 2026. Price and relative-strength answers run through 2026-07-24. Nothing here is estimated, and none of it is a recommendation.